

Completed: 26-Jul-19, 00:21 GMT Released: 26-Jul-19, 10:30 GMT Restricted - External

Jigar Patel +1 212 412 1161 jigar.n.patel@barclays.com BCI, US

A Bottom-up Look at CDX.HY

After rallying sharply from the end of May to early July, CDX.HY drifted wider over the following two weeks before resuming its rally this week. With this week's move, CDX.HY spreads are back within 5bp of the early-July tights, which were the tightest levels for the index since January 2018 (Figure 1). As the index rallied from late May to early July, it started to trade at a richer premium to intrinsic (ie, the tightening in the index outpaced the rally in its underlying constituents, Figure 2). This dynamic increased interest in reverse arbitrage trades, whereby investors bought protection on the index and sold protection on the underlying single names to capture the skew, or the index-intrinsic premium (for more details on reverse arbitrage, see *Dissecting the IG Index Arb*, January 29, 2016).

One implication of the reverse arbitrage trade is that it has contributed to the outperformance of the tighter-trading names in the index. We can illustrate this by bucketing the 99 current constituents of CDX.HY into quintiles based on their spread levels as of May 31 (we exclude Weatherford CDS from our analysis because it has dropped out of the index due to the recent credit event), calculating the average spread change for each one from May 31 to July 23, and then comparing their spread changes to that of CDX.HY. For ease of reference, we identify the quintiles as Tightest, Tight, Average, Wide, and Widest. As Figure 3 shows, the Tightest, Tight, and Average buckets have outperformed CDX.HY and the Wide and Widest buckets in percentage terms, while the Average bucket has also outperformed in absolute terms despite trading 135bp inside of the index spread on May 31. We would place less emphasis on the average spread performance of the Widest bucket, as the credits in this quintile have a very wide range of spreads (therefore, some widening in the very wide names is masking some strong performance from others). But the overall point is that the credits that were already trading tighter than the index on May 31 have, on average, outperformed.

As a result of this outperformance, the underlying constituent spread distribution of CDX.HY has shifted even further to the left (Figure 4). Twenty-four constituents now trade inside of 100bp (versus eight on May 31), 55 constituents trade inside of 200bp, and two-thirds of index constituents trade inside of the index spread. At the other end of the


FIGURE 1
CDX.HY Remains Close to Recent Tights



Note: The time series does not reflect the removal of Weatherford, whose CDS auction was held on July 24. Source: Barclays Research

FIGURE 2

The Richness of the CDX.HY Skew (Index-Intrinsic Basis) Has Driven Recent Reverse Arbitrage Activity



Source: Barclays Research


This document is intended for institutional investors and is not subject to all of the independence and disclosure standards applicable to debt research reports prepared for retail investors under U.S. FINRA Rule 2242. Barclays trades the securities covered in this report for its own account and on a discretionary basis on behalf of certain clients. Such trading interests may be contrary to the recommendations offered in this report. PLEASE SEE ANALYST CERTIFICATIONS AND IMPORTANT DISCLOSURES STARTING AFTER PAGE 5

FIGURE 3
The Tightest Three Quintiles Have Outpaced Index
Performance on a Percentage Basis

Average Spread (bp)						
Quintile	5/31/2019	7/23/2019	Chg	Pct Chg		
1: Tightest	103	66	-36	-35%		
2: Tight	162	120	-42	-26%		
3: Average	257	179	-78	-30%		
4: Wide	484	425	-59	-12%		
5: Widest	1492	1538	46	3%		
CDX.HY	392	324	-68	-17%		

FIGURE 4

The Recent Rally Has Meaningfully Increased the Number of CDX.HY Constituents Trading inside of 100bp



Source: Barclays Research

Source: Barclays Research

distribution, 15 credits currently trade wider than 700bp, which is only two fewer than on May 31. This has resulted in the index's having a very high concentration of very tight-trading credits, a still-high number of wide-trading credits, and fewer credits in the midspread buckets (only 19 credits at 300-700bp).

We think there are two main takeaways from this analysis.

The Upside/Downside of CDX.HY Appears Increasingly Unattractive

The skewed constituent distribution of the index makes it increasingly dependent on the widest-trading constituents to rally. The ten widest credits in CDX.HY trade at an average of 40pts upfront, which on the surface could indicate some potential upside. But with those credits trading at stressed/distressed levels for a reason (typically credit-specific issues), and given their lagging performance in the recent rally, we think this is less likely.


Two other factors contributing to our negative view on the index are overall valuations and the CDS-cash basis. With regard to valuations, as of July 23 (pre-Weatherford removal), the index is trading approximately 20bp away from the roll-adjusted post-crisis tight of 304bp that was reached in June 2014. And with regard to the CDX.HY-cash basis (Figure 5), using index-level spreads, we find that the basis remains at the wider end of the range since January 2018 (currently at the fourth percentile).

Taken together, we think investors can position for CDX.HY underperformance by buying protection on the index outright or by using the options market. Within options, we generally prefer trades such as buying 1x1 put spreads to hedge against a moderate widening.

Investors who want to hedge but are concerned about the wider-trading index constituents rallying could consider a strategy of buying protection on the index and simultaneously selling protection on some of the widest-trading constituents. We think that current levels for such a strategy compare favorably to history. For example, the 90 tightest-trading credits in the index trade at an aggregate spread of 229bp (Figure 6). A strategy that buys protection on these 90 credits by using the index (ie, buys protection on the index and sells protection on the nine widest index constituents) would effectively be getting long protection on these credits at 204bp after factoring in the index skew (but before transaction costs). This is actually tighter than the comparable level for the same strategy when the index reached its post-crisis tight in June 2014.

FIGURE 5

CDX-Cash Basis Remains at the Wider End of the Range since 2018



Note: Chart compares the roll-adjusted CDX.HY spread to the L-OAS of the Bloomberg Barclays High Yield Index. Source: Bloomberg Barclays Indices, Barclays Research

FIGURE 6

The Tightest 90% of CDX.HY Constituents Are Collectively Trading at Historically Tight Levels

Index Spread Calculation	Index Spread
HY32 Intrinsic on July 24, 2019 (ex-WFT)	333bp
Ex-9 Widest Credits (JCP, NMG, FTR, DF, CYH, HOV, CRC, RAD, MNI)	229bp
+Index Skew (-25bp)	204bp
HY22 Intrinsic on June 20, 2014 (ex-TXU)	281bp
Ex-9 Widest Credits (RSH, CZR, FST, TOY, SRAC, IHRT, MBIA, JCP, JNY)	207bp
+Index Skew (+12bp)	219bp

Source: Barclays Research

Take Advantage of the Reverse Arb Technical and Screen for Tight-Trading Index Constituents

For investors who prefer to look for single-name opportunities as opposed to index hedges, we present a screen of index constituents that meet the following criteria:

- Trade tighter than CDX.HY
- Trade at the tighter end of their LTM range (<10th percentile)
- Have exhibited a higher beta to CDX.HY (using daily spread changes over the past year)
 than their current spread ratios to CDX.HY

We use the last constraint to look for credits that have historically moved more relative to CDX.HY than their current ratios versus CDX.HY would imply. We recognize that some of these relationships have likely changed over time, but we think this is a reasonable starting point to screen for tight-trading index names.

The results of the screen are shown in Figure 7. For each constituent, we also provide the average weekly trading volume over the past three months. We do not use volume as part of the criteria since future reverse arbitrage activity could be a source of liquidity for even the less-liquid index constituents.


FIGURE 7
Screen Results: Tight-Trading CDX.HY Constituents with a Higher Historical Beta to CDX.HY Than the Current Spread Ratio to CDX.HY Would Imply

		5y CDS (bp)				
Ticker	Current	1y Range	1y Pctl Rank	Ratio to CDX.HY	1y Beta to CDX.HY	3m Avg Weekly Volume (\$mn)
TSG	45	43-216	3%	0.14	0.21	4
AMD	64	64-211	0%	0.20	0.38	18
CIT	71	68-243	0%	0.22	0.34	13
MDC	75	75-228	0%	0.23	0.40	28
MTG	76	76-268	0%	0.23	0.34	15
TOL	85	85-228	0%	0.26	0.41	25
PHM	93	93-217	0%	0.29	0.44	44
ALLY	96	96-218	0%	0.30	0.35	19
BYD	96	91-255	6%	0.30	0.32	12
RDN	98	98-283	0%	0.30	0.38	29
LEN	98	92-221	3%	0.30	0.41	52
MTOR	134	129-331	3%	0.41	0.45	23
STAR	138	138-440	0%	0.43	0.44	10
AMGFIN	160	152-447	4%	0.49	0.64	14
KBH	165	165-382	0%	0.51	0.63	43
CAR	211	211-499	0%	0.65	0.74	46

Note: Levels as of July 23. Beta calculated using daily spread changes over the past year.


Source: DTCC, Barclays Research

High Yield Average Institutional Trade Volume (\$bn)




Note: Includes both registered and 144A volumes. Source: FINRA TRACE

Flows to High Yield Mutual Funds and ETFs




Note: Daily reporters only. Source: EPFR

High Yield Supply by Sector




Note: 2019 new issue data as of July 24. Source: Bloomberg Barclays Indices

On-the-Run HYCDX versus US High Yield Index (bp)




Source: Barclays Research

High Yield Index Price Distribution by Par (%)



Source: Barclays Research

High Yield Spreads by Credit Quality



Source: Bloomberg Barclays Indices

Analyst Certification

I, Jigar Patel, hereby certify (1) that the views expressed in this research report accurately reflect my personal views about any or all of the subject securities or issuers referred to in this research report and (2) no part of my compensation was, is or will be directly or indirectly related to the specific recommendations or views expressed in this research report.

Important Disclosures:

Barclays Research is produced by the Investment Bank of Barclays Bank PLC and its affiliates (collectively and each individually, "Barclays").

All authors contributing to this research report are Research Analysts unless otherwise indicated. The publication date at the top of the report reflects the local time where the report was produced and may differ from the release date provided in GMT.

Availability of Disclosures:

For current important disclosures regarding any issuers which are the subject of this research report please refer to https://publicresearch.barclays.com or alternatively send a written request to: Barclays Research Compliance, 745 Seventh Avenue, 13th Floor, New York, NY 10019 or call +1-212-526-1072.

Barclays Capital Inc. and/or one of its affiliates does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that Barclays may have a conflict of interest that could affect the objectivity of this report. Barclays Capital Inc. and/or one of its affiliates regularly trades, generally deals as principal and generally provides liquidity (as market maker or otherwise) in the debt securities that are the subject of this research report (and related derivatives thereof). Barclays trading desks may have either a long and / or short position in such securities, other financial instruments and / or derivatives, which may pose a conflict with the interests of investing customers. Where permitted and subject to appropriate information barrier restrictions, Barclays fixed income research analysts regularly interact with its trading desk personnel regarding current market conditions and prices. Barclays fixed income research analysts receive compensation based on various factors including, but not limited to, the quality of their work, the overall performance of the firm (including the profitability of the Investment Banking Department), the profitability and revenues of the Markets business and the potential interest of the firm's investing clients in research with respect to the asset class covered by the analyst. To the extent that any historical pricing information was obtained from Barclays trading desks, the firm makes no representation that it is accurate or complete. All levels, prices and spreads are historical and do not necessarily represent current market levels, prices or spreads, some or all of which may have changed since the publication of this document. Barclays Research Department produces various types of research including, but not limited to, fundamental analysis, equity-linked analysis, quantitative analysis, and trade ideas. Recommendations and trade ideas contained in one type of Barclays Research may differ from those contained in other type

In order to access Barclays Statement regarding Research Dissemination Policies and Procedures, please refer to https://publicresearch.barcap.com/S/RD.htm. In order to access Barclays Research Conflict Management Policy Statement, please refer to: https://publicresearch.barcap.com/S/CM.htm.

All pricing information is indicative only. Prices are sourced from Refinitiv as of the last available closing price at the time of production of the research report, unless another time and source is indicated.

Types of investment recommendations produced by Barclays FICC Research:

In addition to any ratings assigned under Barclays' formal rating systems, this publication may contain investment recommendations in the form of trade ideas, thematic screens, scorecards or portfolio recommendations that have been produced by analysts in FICC Research. Any such investment recommendations produced by non-Credit Research teams shall remain open until they are subsequently amended, rebalanced or closed in a future research report. Any such investment recommendations produced by the Credit Research teams are valid at current market conditions and may not be otherwise relied upon.

Disclosure of other investment recommendations produced by Barclays FICC Research:

Barclays FICC Research may have published other investment recommendations in respect of the same securities/instruments recommended in this research report during the preceding 12 months. To view all investment recommendations published by Barclays FICC Research in the preceding 12 months please refer to https://live.barcap.com/go/research/Recommendations.

Legal entities involved in producing Barclays Research:

Barclays Bank PLC (Barclays, UK)

Barclays Capital Inc. (BCI, US)

Barclays Bank Ireland PLC, Frankfurt Branch (BBI, Frankfurt)

Barclays Bank Ireland PLC, Paris Branch (BBI, Paris)

Barclays Bank Ireland PLC, Milan Branch (BBI, Milan)

Barclays Securities Japan Limited (BSJL, Japan)

Barclays Bank PLC, Hong Kong branch (Barclays Bank, Hong Kong)

Barclays Capital Canada Inc. (BCCI, Canada)

Barclays Bank Mexico, S.A. (BBMX, Mexico)

Barclays Securities (India) Private Limited (BSIPL, India)

Barclays Bank PLC, India branch (Barclays Bank, India)

Barclays Bank PLC, Singapore branch (Barclays Bank, Singapore)

Disclaimer

This publication has been produced by Barclays Research Department in the Investment Bank of Barclays Bank PLC and/or one or more of its affiliates (collectively and each individually, "Barclays"). It has been prepared for institutional investors only and not for retail investors. It has been distributed by one or more Barclays affiliated legal entities listed below. It is provided to our clients for information purposes only, and Barclays makes no express or implied warranties, and expressly disclaims all warranties of merchantability or fitness for a particular purpose or use with respect to any data included in this

publication. To the extent that this publication states on the front page that it is intended for institutional investors and is not subject to all of the independence and disclosure standards applicable to debt research reports prepared for retail investors under U.S. FINRA Rule 2242, it is an "institutional debt research report" and distribution to retail investors is strictly prohibited. Barclays also distributes such institutional debt research reports to various issuers, media, regulatory and academic organisations for their own internal informational news gathering, regulatory or academic purposes and not for the purpose of making investment decisions regarding any debt securities. Media organisations are prohibited from re-publishing any opinion or recommendation concerning a debt issuer or debt security contained in any Barclays institutional debt research report. Any such recipients that do not want to continue receiving Barclays institutional debt research reports should contact debtresearch@barclays.com. Barclays will not treat unauthorized recipients of this report as its clients and accepts no liability for use by them of the contents which may not be suitable for their personal use. Prices shown are indicative and Barclays is not offering to buy or sell or soliciting offers to buy or sell any financial instrument.

Without limiting any of the foregoing and to the extent permitted by law, in no event shall Barclays, nor any affiliate, nor any of their respective officers, directors, partners, or employees have any liability for (a) any special, punitive, indirect, or consequential damages; or (b) any lost profits, lost revenue, loss of anticipated savings or loss of opportunity or other financial loss, even if notified of the possibility of such damages, arising from any use of this publication or its contents.

Other than disclosures relating to Barclays, the information contained in this publication has been obtained from sources that Barclays Research believes to be reliable, but Barclays does not represent or warrant that it is accurate or complete. Barclays is not responsible for, and makes no warranties whatsoever as to, the information or opinions contained in any written, electronic, audio or video presentations of third parties that are accessible via a direct hyperlink in this publication or via a hyperlink to a third-party web site ('Third-Party Content'). Any such Third-Party Content has not been adopted or endorsed by Barclays, does not represent the views or opinions of Barclays, and is not incorporated by reference into this publication. Third-Party Content is provided for information purposes only and Barclays has not independently verified its accuracy or completeness.

The views in this publication are solely and exclusively those of the authoring analyst(s) and are subject to change, and Barclays Research has no obligation to update its opinions or the information in this publication. Unless otherwise disclosed herein, the analysts who authored this report have not received any compensation from the subject companies in the past 12 months. If this publication contains recommendations, they are general recommendations that were prepared independently of any other interests, including those of Barclays and/or its affiliates, and/or the subject companies. This publication does not contain personal investment recommendations or investment advice or take into account the individual financial circumstances or investment objectives of the clients who receive it. The securities and other investments discussed herein may not be suitable for all investors. Barclays is not a fiduciary to any recipient of this publication. Investors must independently evaluate the merits and risks of the investments discussed herein, consult any independent advisors they believe necessary, and exercise independent judgment with regard to any investment decision. The value of and income from any investment may fluctuate from day to day as a result of changes in relevant economic markets (including changes in market liquidity). The information herein is not intended to predict actual results, which may differ substantially from those reflected. Past performance is not necessarily indicative of future results. The information provided does not constitute a financial benchmark and should not be used as a submission or contribution of input data for the purposes of determining a financial benchmark.

United Kingdom: This document is being distributed (1) only by or with the approval of an authorised person (Barclays Bank PLC) or (2) to, and is directed at (a) persons in the United Kingdom having professional experience in matters relating to investments and who fall within the definition of "investment professionals" in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Order"); or (b) high net worth companies, unincorporated associations and partnerships and trustees of high value trusts as described in Article 49(2) of the Order; or (c) other persons to whom it may otherwise lawfully be communicated (all such persons being "Relevant Persons"). Any investment or investment activity to which this communication relates is only available to and will only be engaged in with Relevant Persons. Any other persons who receive this communication should not rely on or act upon it. Barclays Bank PLC is authorised by the Prudential Regulation Authority and regulated by the Financial Conduct Authority and the Prudential Regulation Authority and is a member of the London Stock Exchange.

European Economic Area ("EEA"): This material is being distributed in the EEA by Barclays Bank PLC. Barclays Bank PLC is not registered in France with the Autorité des marchés financiers or the Autorité de contrôle prudentiel.

Americas: The Investment Bank of Barclays Bank PLC undertakes U.S. securities business in the name of its wholly owned subsidiary Barclays Capital Inc., a FINRA and SIPC member. Barclays Capital Inc., a U.S. registered broker/dealer, is distributing this material in the United States and, in connection therewith accepts responsibility for its contents. Any U.S. person wishing to effect a transaction in any security discussed herein should do so only by contacting a representative of Barclays Capital Inc. in the U.S. at 745 Seventh Avenue, New York, New York 10019.

Non-U.S. persons should contact and execute transactions through a Barclays Bank PLC branch or affiliate in their home jurisdiction unless local regulations permit otherwise.

This material is distributed in Canada by Barclays Capital Canada Inc., a registered investment dealer, a Dealer Member of IIROC (www.iiroc.ca), and a Member of the Canadian Investor Protection Fund (CIPF).

This material is distributed in Mexico by Barclays Bank Mexico, S.A.

Japan: This material is being distributed to institutional investors in Japan by Barclays Securities Japan Limited. Barclays Securities Japan Limited is a joint-stock company incorporated in Japan with registered office of 6-10-1 Roppongi, Minato-ku, Tokyo 106-6131, Japan. It is a subsidiary of Barclays Bank PLC and a registered financial instruments firm regulated by the Financial Services Agency of Japan. Registered Number: Kanto Zaimukyokucho (kinsho) No. 143. Asia Pacific (excluding Japan): Barclays Bank PLC, Hong Kong Branch is distributing this material in Hong Kong as an authorised institution regulated by the Hong Kong Monetary Authority. Registered Office: 41/F, Cheung Kong Center, 2 Queen's Road Central, Hong Kong.

All Indian securities-related research and other equity research produced by Barclays' Investment Bank are distributed in India by Barclays Securities (India) Private Limited (BSIPL). BSIPL is a company incorporated under the Companies Act, 1956 having CIN U67120MH2006PTC161063. BSIPL is registered and regulated by the Securities and Exchange Board of India (SEBI) as a Research Analyst: INH000001519; Portfolio Manager INP000002585; Stock Broker/Trading and Clearing Member: National Stock Exchange of India Limited (NSE) Capital Market INB231292732, NSE Futures & Options INF231292732, NSE Currency derivatives INE231450334, Bombay Stock Exchange Limited (BSE) Capital Market INB011292738, BSE Futures & Options INF011292738; Depository Participant (DP) with the National Securities & Depositories Limited (NSDL): DP ID: IN-DP-NSDL-299-2008; Investment Adviser: INA000000391. The registered office of BSIPL is at 208, Ceejay House, Shivsagar Estate, Dr. A. Besant Road, Worli, Mumbai – 400 018, India. Telephone No: +91 2267196000. Fax number: +91 22 67196100. Any other reports produced by Barclays' Investment Bank are distributed in India by Barclays Bank PLC, India Branch, an associate of BSIPL in India that is registered with Reserve Bank of India (RBI) as a Banking Company under the provisions of The Banking Regulation Act, 1949 (Regn No BOM43) and registered with SEBI as Merchant Banker (Regn No INM000002129) and also as Banker to the Issue (Regn No INB100000950). Barclays Investments and Loans (India) Limited, registered with RBI as Non Banking Financial Company (Regn No RBI CoR-07-00258), and Barclays Wealth

Trustees (India) Private Limited, registered with Registrar of Companies (CIN U93000MH2008PTC188438), are associates of BSIPL in India that are not authorised to distribute any reports produced by Barclays' Investment Bank.

This material is distributed in Singapore by the Singapore branch of Barclays Bank PLC, a bank licensed in Singapore by the Monetary Authority of Singapore. For matters in connection with this material, recipients in Singapore may contact the Singapore branch of Barclays Bank PLC, whose registered address is 10 Marina Boulevard, #23-01 Marina Bay Financial Centre Tower 2, Singapore 018983.

This material is distributed to persons in Australia by Barclays Bank PLC. None of Barclays Bank PLC, nor any other Barclays group entity, holds an Australian financial services licence and instead relies on an exemption from the requirement to hold such a licence. This material is intended to only be distributed to "wholesale clients" as defined by the Australian Corporations Act 2001.

Middle East: Nothing herein should be considered investment advice as defined in the Israeli Regulation of Investment Advisory, Investment Marketing and Portfolio Management Law, 1995 ("Advisory Law"). This document is being made to eligible clients (as defined under the Advisory Law) only. Barclays Israeli branch previously held an investment marketing license with the Israel Securities Authority but it cancelled such license on 30/11/2014 as it solely provides its services to eligible clients pursuant to available exemptions under the Advisory Law, therefore a license with the Israel Securities Authority is not required. Accordingly, Barclays does not maintain an insurance coverage pursuant to the Advisory Law.

This material is distributed in the United Arab Emirates (including the Dubai International Financial Centre) and Qatar by Barclays Bank PLC. Barclays Bank PLC in the Dubai International Financial Centre (Registered No. 0060) is regulated by the Dubai Financial Services Authority (DFSA). Principal place of business in the Dubai International Financial Centre: The Gate Village, Building 4, Level 4, PO Box 506504, Dubai, United Arab Emirates. Barclays Bank PLC-DIFC Branch, may only undertake the financial services activities that fall within the scope of its existing DFSA licence. Related financial products or services are only available to Professional Clients, as defined by the Dubai Financial Services Authority. Barclays Bank PLC in the UAE is regulated by the Central Bank of the UAE and is licensed to conduct business activities as a branch of a commercial bank incorporated outside the UAE in Dubai (Licence No.: 13/1844/2008, Registered Office: Building No. 6, Burj Dubai Business Hub, Sheikh Zayed Road, Dubai City) and Abu Dhabi (Licence No.: 13/952/2008, Registered Office: Al Jazira Towers, Hamdan Street, PO Box 2734, Abu Dhabi). Barclays Bank PLC in the Qatar Financial Centre (Registered No. 00018) is authorised by the Qatar Financial Centre Regulatory Authority (QFCRA). Barclays Bank PLC-QFC Branch may only undertake the regulated activities that fall within the scope of its existing QFCRA licence. Principal place of business in Qatar: Qatar Financial Centre, Office 1002, 10th Floor, QFC Tower, Diplomatic Area, West Bay, PO Box 15891, Doha, Qatar. Related financial products or services are only available to Business Customers as defined by the Qatar Financial Centre Regulatory Authority.

Russia: This material is not intended for investors who are not Qualified Investors according to the laws of the Russian Federation as it might contain information about or description of the features of financial instruments not admitted for public offering and/or circulation in the Russian Federation and thus not eligible for non-Qualified Investors. If you are not a Qualified Investor according to the laws of the Russian Federation, please dispose of any copy of this material in your possession.

IRS Circular 230 Prepared Materials Disclaimer: Barclays does not provide tax advice and nothing contained herein should be construed to be tax advice. Please be advised that any discussion of U.S. tax matters contained herein (including any attachments) (i) is not intended or written to be used, and cannot be used, by you for the purpose of avoiding U.S. tax-related penalties; and (ii) was written to support the promotion or marketing of the transactions or other matters addressed herein. Accordingly, you should seek advice based on your particular circumstances from an independent tax advisor.

© Copyright Barclays Bank PLC (2019). All rights reserved. No part of this publication may be reproduced or redistributed in any manner without the prior written permission of Barclays. Barclays Bank PLC is registered in England No. 1026167. Registered office 1 Churchill Place, London, E14 5HP. Additional information regarding this publication will be furnished upon request.

BRCF2242